Lilly Asia Ventures

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Burning Rock Biotech is a precision oncology company that focuses on applying next-generation sequencing (NGS) technology. It offers NGS-based therapy selection testing for late-stage cancer patients, cancer early detection tests moving into the clinical validation stage, and pharmaceutical R&amp;D services. The company’s NGS technology analyzes genetic mutations in tumors to provide personalized cancer treatment recommendations. Its early detection tests use methylation biomarkers and ML algorithms to detect multiple cancer types from blood samples.In&nbsp;<a href="https://ir.brbiotech.com/news-releases/news-release-details/burning-rock-secures-second-ngs-kit-approval-nmpa">March 2022</a>, its Human Nine-Gene Mutation Joint Detection Kit, LungCure CDx, received approval as a class III medical device from China's National Medical Products Administration (NMPA) as the company's second NMPA-approved product. In&nbsp;<a href="https://www.globenewswire.com/en/news-release/2023/09/08/2739852/0/en/Burning-Rock-s-minimal-residual-disease-MRD-product-supports-advancement-in-early-stage-non-small-cell-lung-cancer-treatment-with-results-published-in-the-Cancer-Cell.html">September 2023</a>, Burning Rock commercially launched its personalized minimal residual disease (MRD) assay, brProphet, targeting early-stage cancer patients. Additionally, the company obtained breakthrough device designation from the US FDA and China NMPA for its OverC multi-cancer early detection blood test.Burning Rock reported revenue growth in 2022, driven by strong performance in its in-hospital channel and pharma services business. The company's in-hospital testing volume grew by 23% YoY, while its pharma business saw a 212% increase in revenue due to the backlog execution of contracts, primarily due to delays related to the COVID-19 pandemic.&nbsp;

<div>
 
 Transcenta Holding Limited is a global clinical-stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development, and manufacturing of antibody-based therapeutics. Its lead product candidate is Osemitamab (TST001), a high-affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). Osemitamab has shown potent anti-tumor activities in preclinical tumor xenograft models and is the second most advanced CLDN18.2 targeting antibody being developed globally.
 
 
 Osemitamab was generated using Transcenta's proprietary Immune Tolerance Breaking Technology (IMTB) platform. It kills CLDN18.2 expressing tumor cells through ADCC mechanisms. Leveraging advanced bioprocessing technology, the fucose content of Osemitamab was significantly reduced during production, further enhancing its ADCC activity mediated by NK cells. Osemitamab is being investigated as a potential treatment for various solid tumors, including gastric/gastroesophageal junction (G/GEJ) cancer, pancreatic cancer, and biliary tract cancer.
 
 
 In a Phase I/IIa study (TranStar102), Osemitamab in combination with CAPOX chemotherapy demonstrated encouraging efficacy as a first-line treatment for advanced G/GEJ cancer. Among patients with CLDN18.2 expression, the confirmed overall response rate was 55%, with a median duration of response of 12.7 months and an estimated median progression-free survival of 14 months as of October 2023. preclinical data also supported the synergistic anti-tumor activity of Osemitamab combined with nivolumab and chemotherapy, including in PD-L1 negative tumors.
 
 
 Transcenta has received clearance from regulatory authorities in the US, China, and South Korea to initiate a global Phase III pivotal trial (TranStar301) evaluating Osemitamab in combination with nivolumab and chemotherapy as a first-line treatment for patients with HER2-negative, CLDN18.2 expressing locally advanced or metastatic G/GEJ adenocarcinoma.
 
 
 The company is operating as a publicly listed company, and is traded on the Hong Kong Stock Exchange under the ticker symbol 6628.
 
</div>

<div>
 
 Nucleix is an Israeli cancer diagnostics startup that develops and markets non-invasive tests for early-stage and recurring cancer detection. Its proprietary EpiCheck platform uses a sensitive biochemical assay for the detection of methylation changes and is compatible with both next-generation sequencing (NGS) and polymerase chain reaction (PCR) platforms. The company claims its EpiCheck platform can detect rare cancerous molecules on a background of a large number of normal molecules. The EpiCheck platform is an objective molecular test which does not rely on human interpretation. The output is a clear positive/negative result, with an additional numerical result between 0&ndash;100.
 
 
 Nucleix is developing a series of tests under its EpiCheck brand, beginning with its Bladder EpiCheck testing kit which is marketed in Europe for bladder cancer recurrence and is awaiting 510(k) clearance from the US Food and Drug Administration for commercialization. Additionally, it is also advancing a Lung EpiCheck test toward commercialization, along with other tests for high-risk diseases.&nbsp;&nbsp;
 
 
 Founded in 2008, Nucleix expanded its operations into the US in May 2020. The company secured venture funding of UD 22 million in January 2022 led by Sands Capital, which will be used to develop liquid biopsy tests for early-stage lung cancer detection.
 
</div>

<div>
 
 Rgenta Therapeutics is a biotechnology company focused on discovering and developing small-molecule drugs targeting ribonucleic acid (RNA) to treat oncology and neurological disorders. The company&rsquo;s proprietary drug discovery platform analyzes large genomic data to identify small molecule glues that target RNAs to regulate or alter protein production and functions.&nbsp;&nbsp;
 
 
 The company was formed with experts in small molecule drugs in the fields of genomics and RNA biology.&nbsp;
 
 
 Key Customers and Partnerships
 
 
 In August 2021, the company partnered with brain disease-focused pharma H. Lundbeck A/ to grant Lundbeck the option to exclusively license the development and commercialization of the RNA-targeting small molecule discovery using Rgenta&rsquo;s platform. The company has the potential to earn up to USD 100 million in milestone payments.&nbsp;
 
 
 Funding and Financials
 
 
 The company raised USD 52 million in November 2022 via a 
 <a href="https://sp-edge.com/updates/14968">
 Series A 
 </a>
 funding round led by AZ-CICC Healthcare Investment Fund. The new funds were to be allocated toward advancing its lead programs and pipeline of RNA programs, enhancing its target discovery, and expanding its platform capabilities. 
 
</div>

<div>
 
 The company has developed a liquid-biopsy platform that can illuminate a patient's biological state and serve as the foundation for blood tests to help drugmakers get a picture of patients likely to respond to treatments. The platform is available for research use only (as of October 2023), accessible to both drug developers and academic researchers.
 
 
 
 
 The platform enables comprehensive profiling of dynamic disease-site biology at the gene and pathway level based on a blood draw, after which using molecular biology, transcriptional biology is profiled. Thereafter, by applying a proprietary machine learning platform, it gives interpretable and actionable read outs.&nbsp;
 
 
 
 
 The company claims that its platform was extensively tested having generated over 7,000 genome-wide disease transcriptional profiles on cancers and various other diseases and conditions
 
 
 
 
 In addition, Precede is developing blood-based clinical tests to advance precision use of cancer medicines in clinical practice.&nbsp;
 
 
 
 
 Funding and financials
 
 
 
 
 The company raised USD 57 million in funding 
 in October 2023,
 co-led by 5AM Ventures and Lilly Asia Ventures, who were joined by Illumina Ventures, Bristol Myers Squibb, Osage University Partners, and Qatar Investment Authority (QIA). The funds were expected to be used to expand operations and its R&amp;D efforts.
 
 
 
</div>

<div>
 
 California-based Alumis (previously Esker Therapeutics) is a clinical-stage precision medicine company focused on the discovery, development, and treatment of autoimmune disorders. The company leverages a precision analytics platform, powered by Foresite Labs, consisting of curated genetic, clinical, and medical record data, a systems immunology approach for prospective data collections, and tools for building patient registries.
 
 
 Alumis&rsquo; fully-owned lead pipeline product, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor in Phase 1 clinical trials for treating psoriasis. The company is also conducting preclinical studies of the drug for other autoimmune diseases. In addition, the company is conducting discovery programs for two other undisclosed targets.&nbsp;
 
 
 The company was founded in 2021, launching out of stealth a USD 70 million Series A funding round in May. In January 2022, the company raised USD 200 million in a Series B funding round led by AyurMaya, which will be used to develop its product pipeline with a focus on ESK-001 as well as other immunology programs targeting autoimmune diseases.&nbsp;
 
 
 
</div>

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Innovent Biologics is a leading biopharmaceutical company founded in 2011 with the mission to develop and commercialize innovative and affordable medicines. The company focuses on oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. As of March 2024, Innovent has ten approved products in the Chinese market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), and others. The company's core product, TYVYT, is an anti-PD-1 monoclonal antibody approved across seven indications, making it the most widely approved PD-1 inhibitor in China.
Innovent has a robust pipeline with three new drug applications under review, four assets in Phase III or pivotal trials, and 19 molecules in early clinical development. The company's innovative pipeline spans various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and RNA therapeutics. In oncology, Innovent is advancing the next-generation immunotherapy combinations with ADCs, such as the CLDN18.2 ADC (IBI343) and the EGFR/B7H3 bispecific ADC (IBI3001). The company's metabolic pipeline includes mazdutide, a first-in-class GLP-1R/GCGR dual agonist in late-stage development for weight management.
Innovent has a strong emphasis on global innovation, with its Innovent Academy delivering eight novel molecules into IND-enabling stage in 2023. The company has established large-scale manufacturing facilities in Suzhou and Hangzhou to support global supply. Innovent collaborates with over 30 global healthcare leaders, reinforcing its commitment to advancing biopharmaceutical innovation worldwide.

RemeGen Co., Ltd. (RemeGen) is a leading commercial-stage biopharmaceutical company based in China committed to providing solutions for patients with life-threatening illnesses. RemeGen's primary focus lies in discovering, developing, and commercializing innovative and differentiated biologic drugs, notably monoclonal antibodies and antibody-drug conjugates (ADCs), across key therapeutic areas such as autoimmune diseases, oncology, and ophthalmic disorders.
RemeGen's flagship product, Telitacicept (RC18), is the world's first and first-in-class recombinant B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) dual-target novel fusion protein product for injection. Telitacicept targets two critical cell-signaling molecules, BLyS and APRIL, involved in B-lymphocyte development, effectively reducing B-cell-mediated autoimmune responses implicated in several autoimmune diseases. In November 2023, Telitacicept received marketing approval from China's National Medical Products Administration (NMPA) for treating systemic lupus erythematosus (SLE).
Another groundbreaking product in RemeGen's portfolio is Disitamab Vedotin, China's first original antibody-drug conjugate (ADC). Disitamab Vedotin gained marketing approval from NMPA in June 2021 for treating HER2-expressing locally advanced or metastatic gastric cancer and in December 2021 for urothelial cancer. In August 2021, RemeGen secured an exclusive global (excluding Asia Pacific) licensing agreement with Seagen for Disitamab Vedotin, with potential milestone payments up to USD 2.6 billion and sales royalties ranging from high single digits to over 15%.
RemeGen's product pipeline encompasses numerous innovative drugs in various stages of research, development, and commercialization, including RC28, a dual-target VEGF/FGF innovative fusion protein with potential as a first-in-class ophthalmic treatment, currently in Phase 3 clinical trials.

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for metabolic and pulmonary diseases. The company's platform enables the conversion of biologics and peptide therapeutics into orally available small molecule drugs with enhanced pharmaceutical properties, including improved bioavailability and stability. This is achieved by leveraging structure-based drug discovery and computational chemistry expertise.
Structure Therapeutics targets G-protein-coupled receptors (GPCRs), a family of receptors that sense and respond to external signals. As of September 2022, the company completed Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies for its lead candidate GSBR-1290, a selective GLP-1 receptor agonist targeting type two diabetes mellitus and obesity. Positive results from the Phase 1 billion MAD study in overweight or obese individuals demonstrated significant weight loss supporting once-daily dosing.
In September 2022, Structure Therapeutics also completed a Phase 1 SAD and MAD study for ANPA-0073, targeting the apelin receptor for treating idiopathic pulmonary fibrosis and pulmonary arterial hypertension. The company is additionally advancing a differentiated lysophosphatidic acid one receptor antagonist for idiopathic pulmonary fibrosis.
Structure Therapeutics successfully went public on the Nasdaq in February 2023, raising USD 161 million in an upsized initial public offering. The company was co-founded by Raymond Stevens, Ph.D., a pioneer in structure-based drug discovery, and Schrödinger, a computational physics-based drug design company.

Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational small interfering RNA (siRNA) therapy for the treatment of preeclampsia. Preeclampsia is a severe pregnancy complication characterized by high blood pressure and organ damage, affecting up to 8% of pregnancies worldwide. It leads to approximately 80,000 maternal and 500,000 fetal and newborn deaths globally each year.
CBP-4888 is a subcutaneously delivered siRNA therapeutic that targets soluble fms-like tyrosine kinase-1 (sFlt1), a protein overproduced by the placenta in preeclampsia. This excess sFlt1 enters the mother's bloodstream, causing vascular damage and the symptoms of preeclampsia. By reducing sFlt1 production in the placenta, CBP-4888 aims to ameliorate preeclampsia symptoms like high blood pressure and organ damage, potentially enabling safer prolongation of pregnancy.
In August 2023, CBP-4888 received Fast Track designation from the US FDA for sFlt1-mediated pre-term preeclampsia. Comanche completed a Phase 1 trial in healthy volunteers and received FDA clearance for an Investigational New Drug application in March 2023. In January 2024, the company secured USD 75 million in oversubscribed Series B financing to initiate a clinical study of CBP-4888 in pregnant preeclamptic patients later that year.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Gritstone Bio (formerly known as Gritstone Oncology) is a biotechnology company engaged in developing tumor-specific immunotherapies for various types of cancer and infectious diseases. Its proprietary AI platform, Edge, is designed to predict tumor-specific neoantigens from a routine tumor biopsy. Based on this, the company develops immunotherapies that can drive the patient&rsquo;s immune system to attack and destroy tumors. The company claims its platform has shown a nine-fold improvement in accuracy for predicting tumors in comparison to publicly available approaches.&nbsp;
 
 
 As of March 2024, the company&rsquo;s pipeline included six drug candidates, including its lead product candidate, GRANITE, an individualized immunotherapy in Phase II/III clinical trials for microsatellite stable colorectal cancers, and SLATE, an off-the-shelf immunotherapy candidate, is in Phase II clinical trials for metastatic solid tumors.&nbsp;
 
 
 Key customers and partnerships
 
 
 Gritstone Bio has key customers that develop candidates using its technology. These include partnerships with 1) National Cancer Institute to evaluate a neoantigen cell therapy-vaccine combination using Gritstone&rsquo;s AI platform (
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-and-national-cancer-institute-nci-establish">
 February 2023
 </a>
 ), 2) Gilead Sciences to research and develop a vaccine-based immunotherapy using Gritstone&rsquo;s technology (
 <a href="https://www.gilead.com/news-and-press/press-room/press-releases/2021/2/gilead-sciences-and-gritstone-announce-collaboration-utilizing-gritstones-vaccine-platform-technology-for-hiv-cure">
 February 2021
 </a>
 ), and 3) Bluebird Bio to develop novel cancer cell therapies using Gritstone&rsquo;s AI platform (
 <a href="https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-and-gritstone-oncology-announce-strategic">
 August 2018
 </a>
 ).
 
 
 In addition, it partnered with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines using Genevant&rsquo;s lipid nanoparticle technology (
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-and-genevant-sciences-announce-option-and-license">
 August 2023
 </a>
 ) and with Friends of Cancer Research to join the ctDNA to Monitor Treatment Response (ctMoniTR) Project (
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-partners-friends-cancer-research-friends-ctdna">
 August 2023
 </a>
 ).
 
 
 Funding and financials
 
 
 The company filed for an IPO in September 2018, raising USD 100 million. In 
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-announces-private-placement-450-million">
 October 2022
 </a>
 , the company raised USD 45 million via a private placement in public equity financing. The funds were expected to be used for clinical development of oncology and infectious disease programs and for general corporate purposes.
 
 
 In 
 <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/gritstone-bio-wins-433-million-us-award-covid-vaccine-study-2023-09-27/">
 September 2023
 </a>
 , the company secured a USD 433 million contract from the US government to conduct a mid-stage study of its self-amplifying mRNA Covid-19 vaccine candidate.
 
 
 For 
 <a href="https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-reports-fourth-quarter-and-full-year-2023">
 FY2023
 </a>
 , it reported USD 16.3 million in revenue from collaborations, an 18% decrease YoY. Further, the company reported net losses of USD 138.5 million, increasing 16% YoY.
 
</div>

<div>
 
 Based in Hong Kong, Insilico Medicine focuses on three areas of drug discovery and development: disease target identification, generation of synthetic biology and novel molecules data, and predicting clinical trial outcomes.&nbsp;
 
 
 The company's key focus area is anti-aging interventions; however, there is also a therapeutic focus on areas such as oncology, dermatology, metabolic diseases, neuroscience, and rare diseases. Nearly a quarter of the company&rsquo;s R&amp;D budget is committed toward aging-related diseases.&nbsp;
 
 
 The company collaborates with pharma companies and also has its own pipeline of small molecules targeting many disease areas, which the company aims to license to pharma players later.&nbsp;
 
 
 In a landmark achievement, Insilico announced in November 2021 that it initiated its first in-human clinical trial of its lead drug compound ISM001-055 (INS018_055) for idiopathic pulmonary fibrosis (IPF). It is reportedly the first-ever AI-discovered drug to be tested on a human. Two years earlier, the company announced that the compound was discovered by the company&rsquo;s AI platform in just 46 days compared to the two- to three-year timespan required for traditional drug discoveries. It also completed the entire preclinical stage, from the earliest stages of identifying potential targets, in a record time of 18 months. In February 2023, the candidate became the first to receive an 
 <a href="https://www.genengnews.com/artificial-intelligence/insilico-gains-fdas-first-orphan-drug-designation-for-ai-candidate/">
 orphan drug designation
 </a>
 from the FDA and initiated a global 
 <a href="https://sp-edge.com/updates/19798">
 Phase II clinical trial
 </a>
 in June 2023.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company entered partnerships with several China- and US-based companies, including NVIDIA (May 2024) to launch the Nach0 language processing tool for biomedical and chemical tasks; 
 <a href="https://sp-edge.com/updates/28807">
 InvoX Pharma
 </a>
 (April 2024) to identify potential uses for invoX&rsquo;s pipeline using Insilico&rsquo;s PandaOmics AI platform; 
 <a href="https://sp-edge.com/updates/21805">
 Exelixis
 </a>
 (September 2023) to develop and commercialize an AI-generated cancer treatment, ISM3091; 
 <a href="https://en.prnasia.com/story/archive/3487576_AE87576_0?utm_source=cleartime-customer&utm_medium=email&fbclid=IwAR3GoL4_NIvdPGv5a-d7QgZkNh9pgJSKYzbFawltIe3Jv17rn1ca72ARUR0">
 4B Technologies
 </a>
 (August 2021) to develop innovative small-molecule therapies for neurological diseases; 
 <a href="https://www.prnewswire.com/news-releases/insilico-medicine-announces-an-ai-driven-protac-rd-collaboration-with-arvinas-301351106.html?tc=eml_cleartime&fbclid=IwAR0AQIMqXebdleapMxubR0OqkkSll_CnglrSUa2TuRWXbXliLoHZGOdQRrE">
 Arvinas
 </a>
 (August 2021) to demonstrate the potential of combining AI with proteolysis-targeting chimera (PROTACs); 
 <a href="https://www.eurekalert.org/news-releases/777014">
 Teva Branded Pharmaceutical
 </a>
 (June 2021); and 
 <a href="https://www.eurekalert.org/news-releases/532850">
 APRINOIA Therapeutics
 </a>
 (December 2020).
 
 
 In January 2022, insilico collaborated with 
 <a href="https://www.prnewswire.com/news-releases/fosun-pharma-and-insilico-medicine-announce-a-strategic-ai-driven-drug-discovery-and-development-collaboration-to-jointly-advance-multiple-targets-301457569.html?tc=eml_cleartime">
 Fosun Pharma
 </a>
 to use AI technology in drug discovery and development. The companies completed the second preclinical candidate compound (PCC) for treating solid tumors in 
 <a href="https://sp-edge.com/updates/31232">
 July 2024
 </a>
 .
 
 
 The company also collaborated with big pharma companies 
 <a href="https://www.eurekalert.org/news-releases/490685">
 Pfizer
 </a>
 (January 2020) to utilize Insilico's machine-learning technology and proprietary Pandomics Discovery Platform and 
 <a href="https://sp-edge.com/updates/14409">
 Sanofi 
 </a>
 (November 2022) to develop novel therapeutics across six new targets.
 
</div>

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Akura Medical, a portfolio company of Shifamed LLC, develops a differentiated mechanical thrombectomy platform designed to address the major challenges of venous thromboembolism (VTE). The company's platform is a low-profile solution intended to easily access and efficiently remove large-volume, mixed-morphology clots while eliminating guesswork around the procedure.The platform integrates aspiration and maceration technology, incorporating high-velocity intersecting jets in a 12-F catheter, enabling efficient removal of thrombus regardless of morphology or volume without catheter clogging. It features a soft, atraumatic distal funnel to enhance clot engagement. The platform continuously monitors hemodynamic data through a sensor at the catheter tip, allowing physicians to identify when a clot has been removed. It also includes an integrated port for on-demand contrast injection to visualize the catheter's position relative to the clot.As of November 2024, the system was in the research and development phase and had not received FDA clearance or CE mark approval.

Bringing Life-Saving Biologics to More Patients

Biosimilars

Innovent Biologics, Inc. is a world-class biopharmaceutical company founded in 2011 that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases. The company has built a robust pipeline of 36 valuable assets, including 22 in oncology. As of 2024, Innovent has launched 10 products in the market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar injection), SULINNO (adalimumab biosimilar injection), HALPRYZA (rituximab biosimilar injection), PEMAZYRE (pemigatinib oral inhibitor), olverembatinib, CYRAMZA (ramucirumab injection), Retsevmo (selpercatinib capsules), FUCASO (equecabtagene autoleucel injection) and SINTBILO (tafolecimab injection). The company has four new drug applications under regulatory review, five assets in Phase III or pivotal clinical trials, and 18 more molecules in early clinical stage. Innovent's research and development strategy is centered on global innovation, with a focus on the "IO + ADC" approach in oncology. The company has established manufacturing facilities in Suzhou and Hangzhou, with a total antibody production capacity of 230,000L. In 2023, Innovent reported total revenue of RMB6,206.1 million, an increase of 36.2% compared to 2022.

Longevity Tech

<div>
 
 Based in Hong Kong, Insilico Medicine focuses on disease target identification, generation of synthetic biology and novel molecules data, and predicting clinical trial outcomes. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers, and other modern machine-learning techniques to explore novel targets and design novel molecular structures with desired properties. The company is also focused on discovering and developing innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.
 
 
 
 
 Insilico Medicine's key focus area is anti-aging interventions. There is also a therapeutic focus on areas such as oncology, dermatology, metabolic diseases, neuroscience, and rare diseases.&nbsp;
 
 
 
 
 The company collaborates with pharma companies and also has apipeline of small molecules targeting many disease areas, which the company aims to license to pharma players later. The company also provides several customer-facing tools for registered users, such as Young.AI and Aging.AI, which help to measure multiple predictors and biomarkers of aging.
 
 
 
 
 Insilico Medicine discovered new dual targets in September 2023, targeting aging and related disease using Microsoft BioGPT. The company's R&amp;D team proposed a new approach for predicting therapeutic targets using a large language model specifically trained for bio-medical tasks. Nine potential dual-purpose targets against aging and fourteen major age-related diseases were discovered, with CCR5 and PTH nominated as novel targets for anti-aging.
 
 
 
 As of October 2023, the company had 31 programs in its pipeline and 29 targets.
 
 
 In November 2023, Insilico Medicine partnered with New Zealand-based nutraceutical company SRW Laboratories to develop innovative longevity products focused on extending health span. This alliance aimed to employ AI to sift through natural compounds to identify those that promote healthy aging. Using Insilico's proprietary Pharma.AI platform, the companies intended to generate new therapeutics and forecast the results of clinical trials. The initiative was begun as of November 2023 and the first product suite developed through this partnership was expected to be released in 2024.
 
 
 Funding and financials
 
 
 
 
 The company raised USD 60 million in a Series D funding round in June 2022, which brought its total raised funds to USD 336 million. The funds were earmarked for clinical development and toestablish an AI robotic drug discovery laboratory and a fully robotic biological data factory.
 
 
 
 
 
</div>

RNA Therapeutics

ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on developing next-generation RNA therapeutics. The company utilizes its proprietary RNA targeting platform, which includes technologies for oligonucleotide inhibition, degradation, and editing, along with novel oligonucleotide delivery methods. ADARx is advancing a pipeline of RNA-targeting therapeutics to treat diseases across various therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system disorders.
The company's lead product candidate, ADX-324, represents an innovative approach for treating hereditary angioedema, a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. Early phase 1 clinical data has shown promising results for ADX-324. ADARx is also developing ADX-038 for the treatment of multiple complement-mediated diseases. The company's proprietary targeted delivery PLR platform and broad SPE technology have been validated by clinical data. In August 2023, ADARx announced it had raised USD 200 million in Series C financing to further advance its clinical programs and support development of its pipeline of mRNA silencing or editing candidates.

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

Chimagen Biosciences is a company that is creating a novel class of multi-functional monoclonal antibodies for cancer therapy.

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Rona Therapeutics is an RNA therapeutics platform that enables the discovery, development, and commercialization of modular and programmable RNA medicines. They provide services that include oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics provides the opportunity to develop transformative RNA therapies and disrupt the trajectory of disease treatment across multiple therapeutic areas. Rona Therapeutics is dedicated to true innovation, assisting patients in living healthier and longer lives, and creating an environment that encourages great people to do great things.

Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.

Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.

IMPACT Therapeutics creates new treatments to treat cancer and other life-threatening disorders. The firm is committed to the discovery and development of targeted anti-cancer treatments based on synthetic lethality, hence offering patients novel targeted anti-cancer drugs.

Alumis develops precision medications to treat autoimmune illnesses. The company's analytics platform and understanding of immunologic disorders aid in the development of treatments and medications for autoimmune diseases, allowing patients to alleviate suffering and modify their way of life.

Targeting One is a joint-stock technology firm that creates reagents, software, and other products. It is committed to developing products in the life science and molecular diagnostic enterprise, serving life science, precision medicine, drug development, and health management, by developing molecular diagnostic technologies with multiple indicators, high throughput, automation, pollution prevention, and relatively inexpensive.

ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, and patient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use, single-pass procedure that efficiently removes blood clots.

LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery.

Pixin Technology is a provider of decision-making products for medical imaging using artificial intelligence.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precisely target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored.

Enchannel Medical is a global innovation platform that focuses on electrophysiology and provides atrial fibrillation treatment solution around ''3D mapping + PFA ablation''.

Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Novlead Biotech contributes to a safer and healthier human well-being through our technological innovations.

Langlai Technology is a clinical-stage innovative drug research and development company. Adhering to the dual-drive strategy of synchronously improving the R&D pipeline and platform construction, it has built a full-process new drug R&D process from concept verification, candidate compound screening, preclinical druggability development to clinical research. system.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Yinghe Brain Science is a neuromodulation platform developer

ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.

LavaMed is a China based medical devices manufacturing company.

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Lupeng Pharmaceutical is a clinical-stage company that focuses on the drug discovery and development of novel therapies for cancer treatment.

Pulnovo Medical integrates development, production, and services. Our core products include using pf radiofrequency ablation technology to treat pulmonary hypertension.  The high-frequency ablation equipment and intravascular catheters developed by the company are pioneer inventions with global invention patents. Pulnovo Medical was established in 2013 in 	Wuxi, Anhui.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

ClinChoice Kunling was established in Tianjin inSince its establishment, through its own organic growth and strategic mergers and acquisitions, ClinChoice has more than 3,000 clinical R&D professionals around the world, located in hot cities and regions of domestic and foreign pharmaceutical R&D, and has developed into a local clinical CRO enterprise model supporting innovative drug device R&D. . The company adheres to the connotation of ''Kunxing Zhiyuan · Ling creates the future'', which means to become an ideal partner for the clinical research and development of innovative pharmaceutical devices.

Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.

ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients.  HJB and MabSpace Biosciences merged and created Transcenta.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.

Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.

Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.

CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases.  CinCor has program is CIN-107, a novel aldosterone synthase inhibitor.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

Fengkaili Medical Devices develops ventricular assist devices to treat patients with heart failure. They provide a plan for improving circulation that doctors can use conveniently and patients can afford. They develop therapeutic devices to improve the health of humans with an inclusive solution.

Ionova Life Science is an anti-tumor drug developer dedicated to the development of innovative types of tumor-targeted drugs and tumor immunomodulatory drugs, including oncology, immuno-oncology, and cardiac metabolic diseases. Force contact

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

As China’s leading healthcare platform, MediTrust has launched a range of diverse health insurance products and a broad array of medical and healthcare benefits and services. The Company effectively links pharmaceutical companies, insurers, hospitals and patients, forming a virtuous circle among payers, suppliers of products and services, and customers. By integrating high-quality medical and healthcare resources and health insurance, MediTrust provides families with economical, high quality, and personalized medical and healthcare services and protection.

Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has unique advantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Zentera Therapeutics is a biopharmaceutical company.

Insilico is a company that provides new material development and system construction services with a new high-efficiency/low-cost methodology based on IT and material convergence technology. The company also provides technical consulting for molecular modeling and simulation, regulation and quality control, and manufacturing and production information management solutions.

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Synthekine is an engineered cytokine therapeutics company that creates selective immunotherapies to improve cancer and inflammatory disease treatment paradigms. Using knowledge of cytokine structure and function, the company develops therapeutics that maximize cytokine efficacy while avoiding toxic side effects. Synthekine is developing a broad and deep pipeline of product candidates by leveraging principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms. Modified cytokines, cytokine-enhanced cell therapies, and surrogate cytokine agonists are among the novel immunotherapies.

NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. Founded and managed by a team of biopharma industry leaders and scientists, Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

EdiGene  is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.  Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.

Fortis Therapeutics is immuno-oncology biotech focused on developing new antibody-drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications.

Kelun Biotech is a biopharmaceutical company.It focuses on the research and development, production and sales of innovative drugs

NovoCodex is involved in the research, development, and manufacture of biological products. Its mission is to provide cutting-edge technology to meet clinical needs. In Binhai New City Science and Technology Park, the company has established a biopharmaceutical laboratory with experience and capabilities in genetic engineering construction, cell culture, toxin synthesis, ADC coupling, preparation filling, preclinical research, and clinical research.

FutureGen is a biopharmaceutical company that develops innovative biologics. The company works in the fields of immunology and cancer, concentrating on the creation and commercialization of novel biologics. The STEP (Structure-based Targeted Evolution Platform) from FutureGen is a cutting-edge screening platform designed specifically for protein drug screening. It integrates several technologies to quickly screen and produce the best antibodies. FutureGen has experience in medication development, clinical research, CMC, and quality in the business world.

Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

Abbisko Therapeutics is a drug company dedicated to innovative drug research and development.  The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets. Based in San Mateo, California and Shanghai, Terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in China and globally.

MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company.  They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.

Lilly Asia Ventures

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless